ALPS Medical Breakthroughs ETF SBIO
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.50%
- Net assets
- $161.8M
- Holdings
- 89
- 12-month distribution yield
- Unavailable
- Asset class
- Equity
ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund listed on NYSE Arca in the United States, issued by ALPS. Its category is Equity · Global (equity). Its last price was US$54.55 on 20 Oct 2026. Its expense ratio is 0.5% a year, from its prospectus dated 31 Mar 2026. It reported net assets of US$161.79 million as of 31 May 2026. Its latest holdings report lists 89 holdings as of 31 May 2026. No distributions are recorded for it over the last 12 months.
Fees
- Total annual operating expenses (gross)
- 0.50%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.50%
- Prospectus date
- 31 Mar 2026
- Filed with the SEC
- 30 Mar 2026
Size and reporting
- Net assets
- $161,792,296
- Total assets
- $161,859,853
- Holdings as of
- 31 May 2026
- Report made public
- 29 Jul 2026 (59 days after the month end)
Top holdings
Largest 25 of 89 positions, as of 31 May 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | Alkermes Plc | IE00B56GVS15 | 4.48% | $7.2M | Equity (common) | Ireland | USD |
| 2 | Kymera Therapeutics Inc | US5015751044 | 4.23% | $6.9M | Equity (common) | United States | USD |
| 3 | Celcuity Inc | US15102K1007 | 3.92% | $6.3M | Equity (common) | United States | USD |
| 4 | Mirum Pharmaceuticals Inc | US6047491013 | 3.90% | $6.3M | Equity (common) | United States | USD |
| 5 | Spyre Therapeutics Inc | US00773J2024 | 3.68% | $6.0M | Equity (common) | United States | USD |
| 6 | Cg Oncology Inc | US1569441009 | 3.35% | $5.4M | Equity (common) | United States | USD |
| 7 | Apogee Therapeutics Inc | US03770N1019 | 2.93% | $4.7M | Equity (common) | United States | USD |
| 8 | Xenon Pharmaceuticals Inc | CA98420N1050 | 2.90% | $4.7M | Equity (common) | Canada | USD |
| 9 | Travere Therapeutics Inc | US89422G1076 | 2.77% | $4.5M | Equity (common) | United States | USD |
| 10 | Dianthus Therapeutics Inc | US2528281080 | 2.64% | $4.3M | Equity (common) | United States | USD |
| 11 | Newamsterdam Pharma Co Nv | NL00150012L7 | 2.47% | $4.0M | Equity (common) | Netherlands | USD |
| 12 | Viking Therapeutics Inc | US92686J1060 | 2.41% | $3.9M | Equity (common) | United States | USD |
| 13 | Crinetics Pharmaceuticals Inc | US22663K1079 | 2.37% | $3.8M | Equity (common) | United States | USD |
| 14 | Acadia Pharmaceuticals Inc | US0042251084 | 2.35% | $3.8M | Equity (common) | United States | USD |
| 15 | Edgewise Therapeutics Inc | US28036F1057 | 2.33% | $3.8M | Equity (common) | United States | USD |
| 16 | Denali Therapeutics Inc | US24823R1059 | 2.13% | $3.4M | Equity (common) | United States | USD |
| 17 | Oruka Therapeutics Inc | US6876041087 | 1.81% | $2.9M | Equity (common) | United States | USD |
| 18 | Structure Therapeutics Inc | US86366E1064 | 1.78% | $2.9M | Equity (common) | Cayman Islands | USD |
| 19 | Disc Medicine Inc | US2546041011 | 1.69% | $2.7M | Equity (common) | United States | USD |
| 20 | Ideaya Biosciences Inc | US45166A1025 | 1.65% | $2.7M | Equity (common) | United States | USD |
| 21 | Vera Therapeutics Inc | US92337R1014 | 1.61% | $2.6M | Equity (common) | United States | USD |
| 22 | Tarsus Pharmaceuticals Inc | US87650L1035 | 1.61% | $2.6M | Equity (common) | United States | USD |
| 23 | Relay Therapeutics Inc | US75943R1023 | 1.60% | $2.6M | Equity (common) | United States | USD |
| 24 | Mineralys Therapeutics Inc | US6031701013 | 1.59% | $2.6M | Equity (common) | United States | USD |
| 25 | Celldex Therapeutics Inc | US15117B2025 | 1.33% | $2.2M | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 100.03% | |
| Short-term investment vehicles (cash funds) | <0.01% | |
| Equity derivatives | 0.00% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 80.20% | |
| Netherlands | 4.68% | |
| Cayman Islands | 4.66% | |
| Ireland | 4.48% | |
| Canada | 2.90% | |
| Belgium | 1.19% | |
| United Kingdom | 1.08% | |
| Switzerland | 0.84% | |
| Denmark | 0.00% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 100.04% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 28.10% | |
| Health Technology | 6.49% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- Unavailable
- 12-month yield
- Unavailable
- Frequency
- None in 12 months
- Latest ex-date
- 19 Dec 2024
12-month yield = distributions per unit with an ex-date in the last 12 months ÷ latest price × 100. It is not shown because there were no distributions in the last 12 months.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (2 payments)
| Ex-date | Amount per unit |
|---|---|
| 19 Dec 2024 | $1.1740 |
| 21 Dec 2023 | $0.0710 |
Filings and sources
- Form N-PORT report for May 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000047823) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- SBIO and VT Vanguard Total World Stock Index ETF
- SBIO and SMH VanEck Semiconductor ETF
- SBIO and SOXX iShares PHLX SOX Semiconductor Sector Index Fund
- SBIO and CGDV Capital Group Dividend Value ETF